At 90 days, participants randomized to the Felix NeuroAI transcutaneous peripheral nerve stimulation (TPNS) system showed ...

Cambridge-based biotechnology company Biogen Inc. announced Monday that it will move its global headquarters to a new ...

A new blood test identifies a key biomarker for Alzheimer’s disease, which may help make assessing the presence and stage of ...

Colleges and teaching hospitals are the cornerstones of the city’s economy — and identity. But federal funding cuts to higher ...

Since the Orphan Drug Act went into effect in 1983, more than 600 drugs have been approved for rare diseases, according to ...

Biogen Inc. plans to move its headquarters into a 16-story Kendall Square tower to be developed by MIT and BioMed Realty ...

The results suggested that plasma MTBR-tau243 could help estimate the tauopathy load in Alzheimer's disease, improving ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

AXS-05 was well-tolerated and significantly delayed the time to agitation relapse compared with placebo in patients with ...

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer ...